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NOVELTY AND IMPACT 
The aptly named RAGE protein fuels chronic inflammation. In healthy persons, however, 
soluble forms of RAGE (sRAGE) are abundant in the serum, where they possibly serve as 
decoy receptors to prevent proinflammatory signaling. Here, among stage III-IV melanoma 
patients, decreased serum levels of both sRAGE and the splice variant esRAGE were 
correlated with poor overall survival. By comparison, RAGE protein expression was 
significantly elevated within primary melanoma tissue. The results suggest that RAGE 
signaling influences the advance of melanoma and that sRAGE and esRAGE are 
independent survival indicators in patients at high risk of progression. 
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ABSTRACT 
RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor 
microenvironment. This study links the soluble forms of RAGE (sRAGE and esRAGE) with 
clinical outcome of melanoma patients. Moreover, tissue expression of RAGE was analyzed 
using immunohistochemistry on two independent tissue microarrays (TMA) containing 35 or 
257 primary melanomas, and 41 or 22 benign nevi, respectively. Serum concentrations of 
sRAGE and esRAGE were measured in 229 stage III-IV patients using ELISA and plasma 
concentrations of sRAGE were analyzed in an independent second cohort with 173 samples 
of stage I-IV patients. In this cohort, three well-described SNPs in the RAGE gene were 
analyzed. RAGE protein expression was highly upregulated in primary melanomas compared 
to benign nevi in the two TMA (p < 0.001 and p = 0.005) as well as in sun-exposed 
melanomas (p = 0.046). sRAGE and esRAGE were identified as prognostic markers for 
survival as diminished sRAGE (p = 0.034) and esRAGE (p = 0.012) serum levels correlated 
with poor overall survival (OS). Multivariate Cox regression analysis showed that diminished 
serum sRAGE was independently associated with poor survival (p = 0.009). Moreover, 
diminished sRAGE was strongly associated with impaired OS in the second cohort (p < 
0.001). Multivariate Cox regression analysis including the investigated SNPs revealed an 
independent correlation of the two interacting promoter SNPs with impaired OS. In 
conclusion, the soluble forms of RAGE and variants in its genetic locus are prognostic 
markers for survival in melanoma patients with high risk for progression. 
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INTRODUCTION 
Melanoma initiation, growth and progression have been associated with micro-environmental 
factors which orchestrate tumor-stroma interactions.1,2 However, the importance of these 
factors for predicting disease progression has not yet been established in a clinical setting. In 
the clinical care of melanoma patients, early detection of disease progression by biomarkers 
is crucial to guide treatment decisions and to improve outcome, especially in asymptomatic 
patients with advanced melanoma (stage III or IV following the criteria of the American Joint 
Committee on Cancer [AJCC]). Several serological biomarkers have been described to 
determine the prognosis of patients with distant melanoma metastases.3,4 Among them, 
S100B and lactate dehydrogenase (LDH) are most widely used in clinical practice. However, 
only LDH has been included into the AJCC staging system for patients with stage IV 
melanoma. Moreover, the standard melanoma biomarker S100B lacks sensitivity to detect 
melanoma progression in up to 20% of patients with asymptomatic but image-detected 
metastases.5 Consequently, there remains a high demand for new, valid markers that predict 
the risk of disease progression, particularly in the case of loco-regional and distant 
metastasis with low or even no tumor burden. 
Previously, we have demonstrated that the receptor for advanced glycation end-products 
(RAGE) is a driver of inflammation-associated tumorigenesis by sustaining a chronic 
inflammatory tumor microenvironment.6 The RAGE molecule belongs to the immunoglobulin 
superfamily and represents a membrane-bound pattern-recognition receptor for alarmins.7,8 
Interaction between RAGE and its ligands amplifies the pro-inflammatory response.7 A 
soluble form of RAGE (sRAGE) is known to be generated by shedding via ADAM10 or by 
alternative splicing9 and is abundant in plasma/serum of healthy persons, where it is thought 
to act as decoy for its ligands.7 Total sRAGE mainly consists of both sRAGE cleaved from 
full-length RAGE and esRAGE, a splice variant representing only 20-25 % of total sRAGE 
levels.9-11 RAGE-binding alarmins, also known as damage-associated molecular pattern 
molecules (DAMPs), are released upon damage or cellular stress and are able to activate 
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immune responses similar to cytokines.12-14 The melanoma biomarker S100B belongs to this 
group of danger signaling molecules and is known to interact with RAGE.12,15  
Recently, three naturally occurring, functional genetic variants within the AGER locus 
encoding for RAGE have been studied. The single nucleotide polymorphisms (SNPs) -
429T/C (rs1800625) and -374T/A (rs1800624) are located in the promoter region and have 
been shown to increase transcriptional activity of RAGE.16-18 Presence of these promoter 
SNPs correlates with higher disease activity of various inflammatory diseases such as 
rheumatoid arthritis or Crohn’s disease.19 Furthermore, the SNP G82S in exon 3 affects 
glycosylation of the receptor molecule and thereby enhances ligand binding.16,20 The G82S 
polymorphism is associated with higher activity of various diseases such as Alzheimer’s 
disease21 and correlates with higher risk for diabetic complications.22 To date, the functional 
role of these well-described SNPs within the genetic locus of RAGE have not been studied in 
melanoma patients.  
The aim of this study was to investigate soluble forms of RAGE as putative biomarkers for 
human malignant melanoma. Therefore, measurements of sRAGE in two independent 
cohorts of patients were conducted and the impact of sRAGE on survival was assessed. 
Moreover, the genotypes of the three functional RAGE polymorphisms -429T/C, -374T/A, 
and G82S were determined and their prognostic impact for high-risk melanoma patients was 
evaluated. 
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MATERIALS AND METHODS 
Patients 
For this study, two independent sets of plasma and serum samples from 402 melanoma 
patients (stages I-IV) were analyzed (Table 2). Cohort 1 (marker identification set) consisted 
of 229 stage III/IV patients who had been seen between 2008 and 2013 at the Department of 
Dermatology of the University Hospital Tübingen, Germany. Cohort 2 (marker evaluation set) 
consisted of 173 stage I-IV patients who had been seen between 2010 and 2012 at the 
Department of Dermatology of the University Hospital Heidelberg, Germany. Median follow-
up was 35.5 months for cohort 1 and 13.8 months for cohort 2. Follow-up time was defined 
from the date of blood withdrawal to the date of last follow-up or death. Primary endpoint was 
overall survival (OS). Patients who were alive at the date of last follow-up were censored. 
Samples were selected according to the following criteria: histologically confirmed 
melanoma, complete documentation of medical history, primary tumor characteristics, course 
of the disease, and follow-up. The collection of plasma or serum and documentation of 
clinical data were performed after patients’ informed consent with institutional review board 
approval. Disease staging was done according to the criteria of the AJCC.23 Detailed patient 
characteristics are presented in Table 2. Blood draw was done using gel-coated serum tubes 
or EDTA-coated plasma tubes (Sarstedt). After centrifugation, serum and plasma was stored 
at -20 or -80 °C, respectively. 
Determination of circulating levels of sRAGE and esRAGE 
Concentration of circulating levels of RAGE (sRAGE) and of the endogenous secretory splice 
variant esRAGE were measured in duplicate using sandwich ELISA kits (R&D Systems, 
Minneapolis, MN and B-Bridge International, Tokyo, Japan). S100B serum levels had been 
determined routinely during regular follow-up with Elecsys S100 immunoassay (Roche 
Diagnostics AG, Rotkreuz, Switzerland, ULN = 0.1 ng/mL) according to the instructions of the 
manufacturer, and LDH was determined by conventional central laboratory analysis with an 
ULN = 250 U/L. 
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Receptor-Ligand interaction in vitro 
Freshly collected blood from healthy donors was centrifuged at 3,000 U/min for 15 min. 
Serum was harvested and incubated with bovine S100B (Merck Chemicals Ltd., Nottingham, 
UK) at different final concentrations ranging from 0 mg/L to 100 mg/L at 37°C for 24h. After 
incubation, sRAGE levels were determined via ELISA (R&D Systems, Minneapolis, MN) 
according to the manufacturer’s instructions. 
Tissue Microarray (TMA) 
Two independent TMAs were conducted using formalin fixed and paraffin embedded tissue 
according to a previous report (Table 1).24 Briefly, tissue punch samples (0.6 mm diameter) 
were taken from tumor or nevus tissue, respectively, and collected in a single TMA block 
each. TMA 1 contained 152 valid tissue punches from 36 primary melanomas (35 were 
evaluable) and 41 associated benign nevi in duplicate punches from 26 patients. TMA 2 
contained 279 valid tissue punches from 257 primary melanomas and 22 benign nevi in 
single punches from 279 patients. 
Immunohistochemical staining was performed as described previously.6 Briefly, after 
deparaffinization and antigen retrieval, the slides were washed and incubated with blocking 
serum (0.1% bovine serum albumin in PBS plus 5% normal rabbit serum) for 1 hour followed 
by avidin-biotin blocking reagent. Incubation with a goat IgG polyclonal primary antibody 
against human RAGE (Catalog No. AF1145, R&D Systems, Minneapolis, MN) in a dilution of 
1:400 or with blocking serum for secondary antibody control was performed overnight at 4°C. 
This was followed by incubation with a rabbit anti-goat secondary antibody (Vectastain ABC 
Kit, Vector Laboratories, Burlingame, CA) and followed by incubation with ABC reagent 
(Vectastain ABC Kit, Vector Laboratories, CA). Finally, staining was completed utilizing DAB 
(DAB Peroxidase Substrate Kit, Vector Laboratories, Burlingame, CA). Staining reaction was 
stopped in distilled H2O, and the slide was counter-stained with hematoxylin (Thermo 
Scientific, Waltham, MA).Evaluation of the stained slides was done by two blinded 
experienced investigators. In order to distinguish chromogen DAB from melanin pigment 
parallel sections stained lightly with H&E were used upon evaluation. Staining intensity was 
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analyzed based on pathological scoring as previously described.25 In our study, the intensity 
0 and 1 were combined and named “low intensity” and intensity 2 and 3 were combined and 
named “high intensity” (Supporting Information Figure S6). In case of discordant scoring 
results a consensus score was assigned. TMA spots with a lack of tumor tissue or crush 
artifacts were excluded from the analysis. Tissue samples were divided into sun-exposed vs. 
non sun-exposed based on the evaluation of severe collagen degeneration within the tissue 
punch or in the whole tissue specimen. Statistical significance was calculated by two-sided 
Fisher’s exact test as it is recommended for sample sizes less than 1000. 
Selection of polymorphisms and genotyping 
The three single nucleotide polymorphisms (SNPs) -374T/A (rs1800624), -429T/C 
(rs1800625), and G82S (rs2070600) in the RAGE gene (AGER gene locus) were 
investigated because of either enhancing transcriptional activity (-374T/A and -429T/C) or 
showing enhanced ligand binding (G82S).16,17 Human genomic DNA was obtained from the 
centrifuged blood cells of the EDTA blood samples from cohort 2 by using a kit from Qiagen 
(Valencia, CA, USA) according to manufacturer’s instructions. Genotyping of the SNPs was 
done by using a PCR-based approach (RFLP) that had already been described and 
validated.26 Briefly, for amplification of the region containing the two promoter SNPs (-374T/A 
and -429T/C), the following primers were used: forward primer 5‘-
GGGGCAGTTCTCTCCTCACT-3’ and reverse primer 5’-GGTTCAGGCCAGACTGTTGT-3’. 
For amplification of the region in exon 3 containing the G82S SNP, 5’-
GTAAGCGGGGCTCCTGTTGCA-3’ was used as forward primer, and 5’-
GGCCAAGGCTGGGGTTGAAGG-3’ as reverse primer. For enzyme digestion of the 
resulting PCR products, the enzymes MfeI (for -374T/A) and AluI (for -429T/C and G82S) 
were utilized. 
Statistics 
Cut-off values for marker proteins were calculated utilizing a previously described algorithm 
of maximally selected statistics that accounts for multiple testing and thereby prevents from a 
large alpha error.27 Based on data from the manufacturer of the RAGE ELISA that indicated 
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higher sRAGE levels in serum as compared to plasma, separate cut-off values for serum and 
plasma sRAGE were calculated. Cut-off values for sRAGE used in this study were 1012.07 
pg/mL (serum) and 316.6 pg/mL (plasma).  For serum esRAGE, a cut-off value of 321 pg/mL 
was calculated. 
Estimates of cumulative overall survival probabilities according to Kaplan-Meier were 
compared using two-sided log-rank test statistics. Multivariate Cox proportional hazard 
analyses were used to evaluate the independent effects of sRAGE and the polymorphisms 
on OS. The models were stratified by stage to account for stage-dependent differences, and 
adjustment was made for age and sex of the patients. Results of the Cox models were 
described by means of hazard ratios (HRs) together with 95% confidence intervals (CIs), and 
P values were calculated based on the Wald test. Associations between serum markers were 
calculated by two-sided Spearman’s rank correlation coefficient method. Receiver operating 
curve analyses were calculated using the R package ‘pROC’.28 Relative sRAGE 
concentrations were compared using two-sided Student’s t-test. 
Throughout the analyses, P values less than 0.05 were considered statistically significant. All 
analyses were carried out using R version 3.0.1 (The R Foundation for Statistical Computing, 
Vienna, Austria). 
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RESULTS 
RAGE protein is abundantly expressed in malignant melanoma 
Melanoma tissue-microarray analysis representing 35 primary melanomas and 41 associated 
benign nevi by immunohistochemistry using a specific antibody against RAGE revealed 
abundant expression of RAGE in melanoma and stromal cells but less expression in tissue of 
benign nevi (p < 0.001; Table 1 and Figure 1 A, B). Tissue samples from sun-exposed areas 
presenting signs of UV damage were associated with higher RAGE expression (Figure 1 D) 
in malignant melanoma (p = 0.046) but not in benign nevi (p = 0.36). Cutaneous UV damage 
is thought to play an important role in melanomagenesis.31 For validation, 
immunohistochemical staining intensity of RAGE was analyzed based on a second 
independent tissue-microarray containing 257 primary melanomas and 22 benign nevi. 
Statistical analysis of the resulting pathological scoring again demonstrated a significant 
upregulation of RAGE protein expression in melanoma tissue as compared to benign nevi (p 
= 0.005; Table 1 and Figure 1 C). 
Serum levels of soluble RAGE predict overall survival in stage III/IV melanoma patients 
Previously, diminished levels of soluble forms of RAGE were identified in patients with 
chronic inflammatory diseases such as rheumatoid arthritis.29 Moreover, sRAGE is thought to 
act as a decoy for its ligands and thereby to inhibit RAGE signaling. Based on these findings, 
we hypothesized that sRAGE levels diminish when the soluble receptor engages with one of 
its ligands e.g. with S100B which is abundantly expressed and released by melanoma cells. 
Therefore, serum of healthy donors was incubated with full-length bovine S100B protein with 
increasing concentrations and sRAGE levels were measured 24 hours after. Soluble RAGE 
levels diminished significantly in a S100B concentration-dependent manner (Supporting 
Information Figure S1). Therefore, we assumed that sRAGE might also be diminished in 
melanoma patients, especially in patients with elevated S100B levels, and thereby might bea 
potentially useful biomarker for disease progression. Subsequently, we measured soluble 
forms of RAGE (sRAGE and esRAGE) in the serum of an identification cohort (cohort 1) 
representing 229 stage III-IV melanoma patients (Table 2). As expected, by conducting a 
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small meta-analysis, we found that mean serum sRAGE was lower in the melanoma patients 
of cohort 1 compared to healthy individuals (Supporting Information Figure S2 A). 
Importantly, diminished serum sRAGE levels were identified as being significantly associated 
with impaired survival (p = 0.034; Figure 2 A). The endogenous splice variant esRAGE 
showed similar prognostic impact as sRAGE in cohort 1 (Figure 2 B). Moreover, sRAGE and 
esRAGE correlated significantly as well as ∆sRAGE (i.e. cleaved sRAGE only, representing 
the calculated difference between sRAGE and esRAGE) and esRAGE (Supporting 
Information Figure S3). Therefore, esRAGE measurement was not considered further in 
cohort 2. Receiver operating characteristic (ROC) analysis showed that the combination of 
S100B and sRAGE was able to predict OS better than S100B alone or S100B in combination 
with LDH (Figure 2 C). Moreover, multivariate Cox regression analysis including sRAGE and 
the established biomarkers S100B and LDH as well as stage and sex identified diminished 
sRAGE as an independent prognostic marker for impaired overall survival in two models with 
S100B and LDH, or LDH alone (Table 3). In the first model, LDH did not add independent 
prognostic information, which was probably due to its strong correlation with S100B 
(Spearman’s rho = 0.46, p < 0.001, data not shown). Therefore, we performed Cox 
proportional hazards analysis without consideration of S100B (Table 2, model 2). In this 
second model, LDH and sRAGE correlated both independently with OS. 
Diminished sRAGE is confirmed as a prognostic marker in melanoma patients 
In an approach to validate the prognostic impact of sRAGE in the peripheral blood, we 
measured plasma levels of sRAGE in an independent second cohort (Table 2). Here, 173 
stage I-IV melanoma patients were included for analysis. Median follow-up was 13.8 months. 
Again, mean plasma sRAGE was lower in these patients compared to healthy individuals 
(Supporting Information Figure S2 B). Diminished sRAGE levels were once more associated 
with impaired survival (p < 0.001). In cohort 2, patients with diminished plasma sRAGE levels 
had an unfavorable outcome with a 1-year survival rate of 46.9% whereas patients with 
normal plasma sRAGE levels did significantly better with a 1-year survival rate of 86.9% (p < 
0.001) (Figure 3 A). Interestingly, plasma sRAGE levels stratified subgroups of stage IV 
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patients. M1c patients with diminished sRAGE levels showed drastically reduced overall 
survival (1-year survival rate 33.3%) compared to M1c patients with normal sRAGE levels (1-
year survival rate 63.3%, log-rank p = 0.0052) (Figure 3 B). In contrast, the latter group of 
patients exhibited a comparable 1-year survival rate as M1a/b patients (63.3% vs. 59.2%, 
log-rank p = 0.94). 
Genetic variants of RAGE may predict survival of melanoma patients  
Genetic variants of RAGE have been associated with functional activity of the RAGE 
signaling pathway. In order to investigate for their association with survival of melanoma 
patients, we performed genotyping of three well-described functional SNPs in the RAGE 
gene (G82S, -374T/A, and -429T/C, Supporting Information Figure S4) using a PCR-based 
approach termed restriction fragment length polymorphism (RFLP) using genomic DNA 
obtained from peripheral blood cells of all EDTA blood samples from cohort 2. In our data 
set, no correlation between SNP status and sRAGE plasma levels was observed (G82S: p = 
0.37, -374T/A: p = 0.87, -429T/C: p = 0.98) (Supporting Information Figure S5). Additionally, 
none single SNP was associated with OS (Supporting Information Table S1). However, 
multivariate Cox regression analysis revealed the presence of both promoter SNPs as an 
independent prognostic marker for impaired OS (p = 0.040, Supporting Information Table 
S1).
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DISCUSSION 
RAGE represents a central driver of tumorigenesis by sustaining an inflammatory tumor 
microenvironment.6 Moreover, damage-associated molecular pattern molecules (DAMPs) 
and its receptors such as RAGE have gained further interest recently as the role of tumor-
promoting inflammation has been identified as an attractive target of innovative anti-tumor 
therapies.30,31 This study explores the importance of the DAMP receptor RAGE as a clinically 
useful prognostic biomarker of disease progression in melanoma patients.  
Using two independent tissue-microarrays, our study revealed abundant expression of RAGE 
protein in malignant melanoma compared to benign nevi. RAGE expression has been 
detected in various types of cancer, e.g. colorectal, pancreatic and squamous cell carcinoma 
and its expression has been correlated with more aggressive types of cancer.14,32-36 This 
supports previous findings of RAGE expression in various melanoma cell lines.37,38 Moreover, 
genetic evidence in various mouse models has revealed RAGE as a central receptor that 
promotes inflammation-associated tumorigenesis.6,39-41 In our study, RAGE protein 
expression was abundant in melanoma tissue compared to benign nevi underlining the 
importance of RAGE in melanomagenesis. Additionally, its high expression in melanomas 
with chronic UV damage sheds light on a possible role of RAGE signaling in the process of 
UV-associated melanoma development.31 
In order to translate these findings to the clinical challenge of early detection of progressing 
melanoma patients, we evaluated the presence of circulating soluble forms of RAGE in 
serum/plasma of melanoma patients and its ability to predict overall survival. Using two 
independent patient cohorts, we demonstrated that diminished levels of a circulating soluble 
form of RAGE (sRAGE) in the peripheral blood of melanoma patients independently predict 
overall survival.  
LDH and S100B are the most commonly used melanoma markers in clinical routine, and 
both have been shown to be reliable markers for survival of patients with distant metastasis 
(AJCC stage IV). Nevertheless, there is still a need for new biomarkers as the standard 
melanoma biomarker S100B fails to detect melanoma progression in up to 20% of patients.5 
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By including sRAGE, S100B, and LDH in a multivariate Cox proportional hazards model, we 
demonstrated that serum sRAGE independently provides additional prognostic information 
compared to the established biomarkers. Although sRAGE has not been studied in 
melanoma patients so far, diminished serum sRAGE levels have been observed in other 
forms of cancer (e.g. breast cancer26, lung cancer42, and pancreatic cancer43). Diminished 
levels of esRAGE were associated with a higher risk for developing pancreatic cancer within 
the first two years of follow-up.44 In addition to these data, elevated levels of the RAGE 
ligands S100A8/A9 and HMGB1 have already been described in sera of cancer patients (e.g. 
colorectal, prostate, breast or oral squamous cell cancer).45 
RAGE expression is ubiquitous and can be detected not only in melanoma cells but also in 
various immune cells and in endothelial cells.7,8 sRAGE is released from these cells to the 
extracellular space and thought to consist of distinct variants of the receptor for advanced 
glycation end-products: predominantly (1) cleaved forms of membrane-bound full-length 
RAGE shed by metalloproteinases like ADAM10 and MMP9 - both abundant in the tumor 
microenvironment, (2) the endogenous splice variant esRAGE representing approximately 
20-25% of total sRAGE levels, and (3) other splice variant forms of RAGE.8,9,1010,47 Moreover, 
previous studies were not able to detect full-length RAGE in the peripheral blood suggesting 
cellular damage or necrosis an unlikely way of release.10 Otherwise, the quest for the cell-
type specific source of sRAGE needs to be addressed by further studies. To evaluate 
whether the prognostic potential of total sRAGE is due to the cleaved form or the 
endogenous splice variant, we measured esRAGE in the serum samples of cohort 1. In our 
study, sRAGE and esRAGE levels seemed to be coordinately released to the peripheral 
blood as both markers correlated strongly. Additionally, a similar correlation is seen with 
esRAGE and cleaved sRAGE (= ∆sRAGE), i.e. sRAGE minus esRAGE (Supporting 
Information Figure S3). This supports recent studies demonstrating a strong similarity 
between total sRAGE and esRAGE levels.11 
The correlation between diminished levels of sRAGE and impaired survival supports the 
hypothesis, that sRAGE serves as a decoy for RAGE activating ligands thereby blocking 
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cellular RAGE-RAGE ligand engagement and subsequently preventing cellular RAGE-
mediated membrane-bound RAGE and thereby inhibits RAGE down-stream signaling.7,15,46 
sRAGE therefore could act as an intrinsic inhibitor of RAGE. Moreover, the S100B 
concentration-dependent decrease of sRAGE in vitro could at least partly explain diminished 
sRAGE levels in cancer patients and melanoma patients with impaired survival. It seems 
likely that RAGE-specific ELISA capture and detection antibodies are not able to bind RAGE 
molecules anymore when their binding sites are occupied by ligands. However, the S100B 
concentration at which sRAGE diminished in vitro was much higher than S100B 
concentrations one would expect in patients’ sera. This is explained by the fact that RAGE 
ligands other than S100B are additionally upregulated in the serum of melanoma patients. 
Moreover, S100B concentrations could be much higher at the tumor site and in its 
microenvironment than in the peripheral blood. However, additional studies are required to 
clarify whether diminished sRAGE levels in melanoma patients with poor prognosis solely 
result from increasing levels of RAGE ligands such as S100B, S100A8/A9, or HMGB1, or 
whether they result from diminished release or enhanced down-regulation in melanoma or 
stromal cells to the benefit of enhanced expression of full-length RAGE. The latter hypothesis 
is supported by the notion that sRAGE levels add significant prognostic impact to the 
multivariate model independently of S100B, and that sRAGE serum levels did not correlate 
with S100B (Spearman’s rho = -0.09, p = 0.17). However, the positive predictive value (PPV) 
of sRAGE alone was relatively low (Cohort 1: PPV = 0.380, Cohort 2: PPV = 0.474) possibly 
due to a relatively high number of high risk patients in cohort 1 (n = 100 for patients with low 
serum sRAGE compared to n = 129 for patients with high serum sRAGE) or a shorter follow-
up period in cohort 2 leading to a biased PPV calculation. Despite these data, the 
combination of S100B and sRAGE was a better predictor of overall survival than S100B 
alone or S100B in combination with LDH (sRAGE and S100B: PPV = 0.826, S100B alone: 
PPV = 0.700, S100B and LDH: PPV = 0.762).  
Upregulation of RAGE expression and release of soluble forms have been linked to 
functional genetic variants of RAGE16,17 and naturally-occurring or acquired SNPs (single 
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nucleotide polymorphisms) of relevant genes have been implicated in melanoma 
pathogenesis.48 Naturally-occurring, functional genetic variants within the AGER locus 
encoding for RAGE have been described recently. The SNPs -429T/C (rs1800625) and -
374T/A (rs1800624) are situated in the AGER promoter region and have been shown to 
increase transcriptional activity of RAGE.16-18 However, the functional role of these well-
described SNPs within the genetic locus of RAGE has not been studied in melanoma 
patients so far. The variants of the two promoter SNPs (-374T/A, and -429T/C) showed a 
significant interaction and were associated with significantly impaired survival in a 
multivariate analysis, but not in univariate analysis (data not shown). Several reports have 
linked genetic variants of RAGE with an impaired prognosis of various cancer types e.g. 
gastric or lung cancer.49,50 Moreover, the aforementioned findings highlight the importance of 
RAGE transcriptional activity in cancer and inflammation, since an association to these 
promoter SNPs is detected with higher disease activity of various inflammatory diseases 
such as rheumatoid arthritis or Crohn’s disease.19 Further evaluation of SNPs in the AGER 
locus using larger patient cohorts and extended genomic analyses will be required to clarify 
the role of genetic variants of RAGE in malignant melanoma. 
Besides its role as prognostic marker in melanoma patients, RAGE signaling may serve as 
an attractive therapeutic target in melanoma. Possible strategies for inhibiting RAGE 
signaling using recombinant sRAGE, inhibitory antibodies against RAGE or its ligands, or 
small-molecule inhibitors have already demonstrated inhibitory effects on tumor growth in 
various mouse models.34,37,46,51,52  
Despite its retrospective nature and restricted sample size, that limits subgroup analyzes, 
this study is the first to establish sRAGE as an independent prognostic blood-based marker 
for survival in melanoma patients with a high risk for progression. Together with the abundant 
expression of RAGE in malignant melanoma compared to benign nevi, this study supports 
the hypothesis that RAGE signaling might play an important role in melanoma. Further 
studies are required to validate these findings and to further investigate the implications of 
variants with its genetic locus on RAGE expression and prognosis of melanoma patients. In 
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conclusion, these data encourage the conduct of further experiments that focus on RAGE 
signaling as putative driving force of melanoma progression and on blocking strategies that 
may involve enhancement of sRAGE production as therapeutic option for melanoma therapy. 
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FIGURE LEGENDS 
 
Figure 1. (A) Representative microphotographs of a two independent tissue-microarrays 
containing primary melanomas and benign nevi analyzed by immunohistochemistry using a 
specific antibody against RAGE. Scale bars 100µm (lower magnification), 50µm (higher 
magnification). (B) Staining intensity of RAGE in 35 primary melanomas and 41 associated 
benign nevi of TMA 1, and (C) in 257 primary melanomas and 22 benign nevi of TMA 2 
based on pathological scoring. (D) Staining intensity of RAGE in sun-exposed vs. non sun-
exposed melanomas of TMA 1. Severe collagen degeneration was interpreted as sign of sun 
exposure. Statistical significance between patient numbers with low or high staining intensity 
was calculated by two-sided Fisher’s exact test (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
Figure 2. Kaplan-Meier estimates of overall survival of the 229 stage III/IV melanoma 
patients from cohort 1 according to serum concentration of (A) sRAGE and (B) esRAGE. 
Cut-off values were 1012.07 ng/L for sRAGE and 321 ng/L for esRAGE. Statistical 
differences were calculated by two-sided log-rank test. (C) The predictive ability of the 
combination of S100B and sRAGE compared with S100B and LDH, and single markers by 
receiver operating characteristic (ROC) curves. The resulting AUC (area under the curve) 
values show that the combination of S100B and sRAGE was the best predictor of overall 
survival. 
 
Figure 3. (A) Kaplan-Meier estimates of overall survival of the 173 stage I-IV melanoma 
patients from cohort 2 according to plasma concentration of sRAGE with a cut-off value of 
316.6 ng/L. P value was calculated by two-sided log-rank test. (B) Kaplan-Meier estimates of 
overall survival of the 64 stage IV melanoma patients from cohort 2 according to M stage and 
plasma concentration of sRAGE. P value was calculated by two-sided log-rank test 
considering all stage IV patients. 
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Table 1. Detailed description of the two independent tissue-microarrays. 
 
Table 2. Patient characteristics at the time point of blood withdrawal for serum analysis. 
 
Table 3. Multivariate Cox regression models for overall survival in cohort 1. 
 
Supporting Information Figure S1. (A) Measured and (B) mean relative concentrations of 
sRAGE in human serum of healthy donors (n = 4) after incubation with bovine S100B at 
different concentrations. The resulting relative mean concentration of sRAGE showed a 
significant S100B concentration-dependent drop compared to mean relative sRAGE 
concentration at a resulting S100B concentration of 12.5 mg/L. Data shown in (B) are mean 
± standard error of the mean (SEM) and statistical differences were calculated by two-sided 
Student’s t-test. **p < 0.01, ***p < 0.001. 
 
Supporting Information Figure S2. Meta-analysis of mean (A) serum sRAGE and (B) 
plasma sRAGE levels in healthy controls from all published articles between 2005 and 2013 
containing at least 20 healthy controls from Caucasian ancestry and graphical comparison 
with mean sRAGE levels of the melanoma patients from cohorts 1 and 2. Melanoma patients’ 
mean sRAGE levels are depicted as yellow bars, mean sRAGE levels of healthy controls are 
depicted as blue bars. Error bars represent standard error of the mean (SEM). 
References: 
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Supporting Information Figure S3. Correlations between serum levels of (A) sRAGE and 
esRAGE, and (B) ∆sRAGE and esRAGE, calculated by two-sided Spearman’s rank 
correlation coefficient. ∆sRAGE was calculated as the difference between measured sRAGE 
concentration and measured esRAGE concentration. sRAGE and esRAGE concentrations 
were measured in the 229 serum samples of cohort 1.  
 
Supporting Information Figure S4. Schematic of three well-described SNPs (single 
nucleotide polymorphisms) within the AGER locus on chromosome 6 encoding for RAGE. 
 
Supporting Information Figure S5. Correlations between SNP status and sRAGE plasma 
levels, calculated by two-sided Spearman’s rank correlation coefficient.  
 
Supporting Information Figure S6. RAGE protein expression in benign nevi (A-D) and 
primary melanomas (E-G) analyzed by immunohistochemistry: (A) Absent (B,E) weak, (C,F) 
moderate and (D,G) strong expression. (A) and (B,E) were considered “low intensity” and 
(C,F) and (D,G) “high intensity” RAGE protein expression. There was no primary melanoma 
lacking RAGE expression completely. 
 
Supporting Information Table S1. Multivariate analysis of overall survival for RAGE 
polymorphisms. The combination of the promoter SNPs (single nucleotide polymorphisms) -
374T/A and -429T/C was independently associated with impaired survival. 
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    TMA 1   TMA 2 
TMA characteristics n %   n % 
TMA Spots Total spots 154 100.0 305 100.0 
Valid spots 152 98.7  279 91.5 
 Missing spots 2 1.3  26 8.5 
       
Patients
#
 No. of patients 26 100.0  279 100.0 
 Mean follow-up [months 
(range)] 
37.8 (2-73)  84.2 (1-186) 
 Clinicopathological characteristics n %   n % 
Age Mean [years (range)] 64.0 (43-90) 55.9 (14-89) 
Sex Male 16 61.5   147 52.7 
Female 10 38.5 132 47.3 
Histology Melanoma 35 100.0   257 100.0 
 
SSM 19 54.3 203 78.9 
NMM 9 25.7 17 6.6 
 
LMM 1 2.9 25 9.7 
 
ALM 2 5.7 9 3.5 
 
not classifiable 4 11.4 3 1.3 
 T classification* Tis 1 2.9 0 0 
 
T1 10 28.6 165 64.2 
 
T2 13 37.1 50 19.5 
 
T3 9 25.7 25 9.7 
 
T4 2 5.7 17 6.6 
 Ulceration No 26 72.2 239 93.0 
Yes 10 27.8 18 7.0 
 Histology Benign nevi 41 100.0   22 100.0 
compound 18 43.9 10 45.5 
junctional 9 22.0 5 22.7 
lentiginous 7 17.1 3 13.6 
dermal 6 14.6 3 13.6 
Nevus bleu 1 2.4 1 4.6 
not classifiable 0 0 0 0 
              
Abbreviations: SSM, superficial spreading melanoma; NMM, nodular melanoma; LMM, lentigo maligna 
melanoma; ALM, acro-lentiginous melanoma. 
*Tumor classification was performed according to the 2009 AJCC melanoma staging system of the 
American Joint Committee on Cancer. 
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Table 2 – Wagner et al. 
 
 Cohort 1  Cohort 2 
Characteristic No.  %  No.  % 
No. of patients 229  100.0  173  100.0 
Sex 
    Female 
    Male 
 
99 
130 
  
43.2 
56.8 
 
  
75 
98 
 
  
43.4 
56.6 
Age at Blood Withdrawal (mean) 
    Range 
59.6 
16-88 
 60.5 
24-84 
Localization of primary 
    Extremities 
    Trunk 
    Unknown 
 
109 
91 
29 
  
47.6 
39.7 
12.7 
  
65 
90 
18 
 
  
37.6 
52.0 
10.4 
 
Histological type of primary 
    Superficial spreading 
    Nodular 
    Lentigo maligna 
    Acrolentiginous 
    Other or NA 
    Occult 
 
83 
51 
4 
30 
26 
35 
  
36.2 
22.3 
1.7 
13.1 
11.4 
15.3 
  
36 
35 
8 
9 
74 
11 
 
  
20.8 
20.2 
4.6 
5.2 
42.8 
6.4 
 
Tumor staging* 
    Stage I 
        IA 
        IB 
    Stage II 
        IIA 
        IIB 
        IIC 
    Stage III 
        IIIA 
        IIIB 
        IIIC 
    Stage IV 
        M1a 
        M1b 
        M1c 
 
 
 
 
 
 
 
 
160 
21 
82 
57 
69 
1 
12 
56 
  
 
 
 
 
 
 
 
69.9 
9.2 
35.8 
24.9 
30.1 
0.4 
5.2 
24.5 
  
34 
12 
22 
28 
18 
8 
2 
47 
12 
21 
14 
64 
9 
4 
51 
  
19.7 
6.9 
12.7 
16.2 
10.4 
4.6 
1.2 
27.2 
6.9 
12.1 
8.1 
37.0 
5.2 
2.3 
29.5 
NOTE. Patient characteristics at the time point of blood withdrawal for serum analysis. 
Abbreviations: NA, not applicable. 
*Tumor staging was performed according to the 2009 AJCC melanoma staging system of the American 
Joint Committee on Cancer. 
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Table 3. Multivariate Cox regression models for overall survival in cohort 1 
     Model 1  Model 2 
Prognostic factor n % dead HR (95% CI)  P  HR (95% CI)  P 
Stage of disease 
    Stage III 
    Stage IV 
 
160 
69 
 
 
15.0% 
66.7% 
 
 
1 
6.1 (3.4-11.0) 
 
 
 
<0.001 
 
 
1 
9.3 (5.5-15.8) 
 
 
 
<0.001 
S100B 
    normal 
    elevated 
 
179 
50 
 
 
19.6% 
70.0% 
 
 
1 
3.4 (1.9-6.0) 
 
 
 
<0.001 
 Not considered   
LDH 
    normal 
    elevated 
 
197 
32 
 
 
26.4% 
56.3% 
 
 
1 
1.3 (0.7-2.4) 
 
 
 
0.325 
 
 
1 
2.1 (1.2-3.6) 
 
 
 
0.012 
sRAGE 
    normal 
    diminished 
 
129 
100 
 
 
24.8% 
38.0% 
 
 
1 
1.9 (1.2-3.1) 
 
 
 
0.009 
 
 
1 
1.7 (1.0-2.7) 
 
 
 
0.035 
NOTE: Both models were adjusted for the confounding effects of sex. Significant results are shown in bold. 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
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Figure 1. (A) Representative microphotographs of a two independent tissue-microarrays containing primary 
melanomas and benign nevi analyzed by immunohistochemistry using a specific antibody against RAGE. 
Scale bars 100µm (lower magnification), 50µm (higher magnification). (B) Staining intensity of RAGE in 35 
primary melanomas and 41 associated benign nevi of TMA 1, and (C) in 257 primary melanomas and 22 
benign nevi of TMA 2 based on pathological scoring. (D) Staining intensity of RAGE in sun-exposed vs. non 
sun-exposed melanomas of TMA 1. Severe collagen degeneration was interpreted as sign of sun exposure. 
Statistical significance between patient numbers with low or high staining intensity was calculated by two-
sided Fisher’s exact test (*p < 0.05; **p < 0.01; ***p < 0.001).  
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Figure 2. Kaplan-Meier estimates of overall survival of the 229 stage III/IV melanoma patients from cohort 1 
according to serum concentration of (A) sRAGE and (B) esRAGE. Cut-off values were 1012.07 ng/L for 
sRAGE and 321 ng/L for esRAGE. Statistical differences were calculated by two-sided log-rank test. (C) The 
predictive ability of the combination of S100B and sRAGE compared with S100B and LDH, and single 
markers by receiver operating characteristic (ROC) curves. The resulting AUC (area under the curve) values 
show that the combination of S100B and sRAGE was the best predictor of overall survival.  
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Figure 3. (A) Kaplan-Meier estimates of overall survival of the 173 stage I-IV melanoma patients from 
cohort 2 according to plasma concentration of sRAGE with a cut-off value of 316.6 ng/L. P value was 
calculated by two-sided log-rank test. (B) Kaplan-Meier estimates of overall survival of the 64 stage IV 
melanoma patients from cohort 2 according to M stage and plasma concentration of sRAGE. P value was 
calculated by two-sided log-rank test considering all stage IV patients.  
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